We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Applied Therapeutics Inc | NASDAQ:APLT | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.23 | 5.08% | 4.76 | 4.63 | 9.10 | 4.86 | 4.605 | 4.63 | 622,610 | 05:00:04 |
From Nov 2023 to May 2024
By Colin Kellaher
Applied Therapeutics shares rose sharply and hit a new 52-week high on Wednesday after the clinical-stage biopharmaceutical company reported a pair of regulatory advances for its lead product candidate.
Shares of the New York company were recently changing hands at $3.98, up 9.2%, after touching a 52-week high of $4.42 earlier in the session.
Applied said it filed last month for U.S. Food and Drug Administration approval of govorestat for the treatment of classic galactosemia, a rare genetic metabolic disease for which there is currently no available treatment.
The company also said the European Medicines Agency has validated and accepted for review its application seeking approval of the drug in the European Union.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 03, 2024 11:05 ET (16:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Applied Therapeutics Chart |
1 Month Applied Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
